SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from ...

Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE ...

(MENAFN- GlobeNewsWire - Nasdaq) Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

We have updated our Privacy Policy. Please review to learn more. By continuing to use our services, you agree to these updates. By Patty Nieberg Published May 6, 2026 ...

Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines Data from this trial previously prompted the Food and Drug Administration (FDA) to grant orphan drug designation to ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Dubai: Heavy rain hit some areas of eastern regions in UAE on Sunday, August 10, at around 4.30 pm, while other parts of the country saw cloudy to partly cloudy skies. Dusty conditions with low ...